The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

Adeno-associated virus (AAV) vectors have become widely recognized as a fundamental tool in gene therapy, primarily due to their potential as a delivery system for the treatment of genetic disorders.

Range of Methods Used in Generating and Purifying AAV Vectors Vectors derived from adeno-associated virus (AAV) provide promising gene delivery vehicles that can be used effectively in large-scale ...

DUBLIN--(BUSINESS WIRE)--The "Adeno Associated Virus Vector Manufacturing Market Size, Share & Trends Analysis Report By Scale Of Operations (Clinical, Commercial), By Method, By Application, By ...

Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately ...

PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and ...

In a recent review published in Signal Transduction and Targeted Therapy, researchers presented recombinant adeno-associated virus (rAAV)-based genetic applications to treat human diseases. Study: ...

Non-human primate study results demonstrate improvements in skeletal and cardiac muscle delivery efficacy, safety potential, human translatability, and manufacturability over prior AAV capsids ...

Journal in the field and provides all-inclusive access to the critical pillars of human gene therapy: research, methods, and clinical applications. Recent clinical trials utilizing high doses of adeno ...

Recombinant adeno-associated viruses (AAVs), lentiviral vectors (LVV), and adenovirus (Ad) are the leading viral vectors for cell and gene therapy. Like other biologics, these viral vectors require ...